Private Health Insurance In China: Keeping Up With The Evolving Payor System
The global pharmaceutical industry faces challenges in tapping into China’s booming health care market; coverage under public insurance is still very limited and what patients can afford to spend out-of-pocket is still inadequate for high-cost innovative medicines. Can private health insurance close the gap?
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.